Phaseline

Targets › SLC10A2

SLC10A2 (Ileal sodium/bile acid cotransporter): drug programs, companies and trials

4 programs from 3 companies in 8 trials: 4 Phase 3, 3 Phase 2, 1 Phase 4; Gastroenterology, Other, Respiratory; next expected readout Jan 2027.

Plays a critical role in the sodium-dependent reabsorption of bile acids from the lumen of the small intestine. Transports various bile acids, unconjugated or conjugated, such as cholate and taurocholate. (UniProt, Q12908)

Open in Phaseline: the race on SLC10A2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Mirum PharmaceuticalsMaralixibat
Ileal bile acid transporter inhibitor
SLC10A2Phase 4Alagille Syndrome; Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC); Constipation Chronic IdiopathicFeb 2027
Albireo, an Ipsen CompanyOdevixibat
Ileal bile acid transporter inhibitor
SLC10A2Phase 3Biliary Atresia; Alagille SyndromeFeb 2027
GSKLinerixibat
Ileal bile acid transporter inhibitor
SLC10A2Phase 3Cholestasis–
Mirum PharmaceuticalsVolixibat
Ileal bile acid transporter inhibitor
SLC10A2Phase 2Primary Biliary Cholangitis; Primary Sclerosing CholangitisJan 2027

Conditions

Alagille Syndrome (2) Cholestasis (1) Biliary Atresia (1) Primary Biliary Cholangitis (1) Primary Sclerosing Cholangitis (1) Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC) (1) Constipation Chronic Idiopathic (1)

Modalities

small molecule (4)

Companies

Mirum Pharmaceuticals (2) GSK (1) Albireo, an Ipsen Company (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.